DKK349.30
3.80% today
Copenhagen, Jul 21, 04:59 pm CET
ISIN
DK0060257814
Symbol
ZEAL
Sector
Industry

Zealand Pharma Stock price

DKK349.30
-19.30 5.24% 1M
-382.20 52.25% 6M
-366.20 51.18% YTD
-530.70 60.31% 1Y
+222.50 175.47% 3Y
+116.30 49.91% 5Y
+215.80 161.65% 10Y
+263.30 306.16% 20Y
Copenhagen, Closing price Mon, Jul 21 2025
-13.80 3.80%
ISIN
DK0060257814
Symbol
ZEAL
Sector
Industry

Key metrics

Basic
Market capitalization
DKK25.8b
Enterprise Value
DKK17.7b
Net debt
positive
Cash
DKK8.5b
Shares outstanding
70.7m
Valuation (TTM | estimate)
P/E
negative | 54.1
P/S
464.1 | 6.7
EV/Sales
317.8 | 4.6
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
90.7%
Return on Equity
-12.5%
ROCE
-16.0%
ROIC
-588.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
DKK55.7m | DKK3.9b
EBITDA
DKK-1.4b | DKK565.6m
EBIT
DKK-1.4b | DKK5.9b
Net Income
DKK-1.2b | DKK474.6m
Free Cash Flow
DKK-1.2b
Growth (TTM | estimate)
Revenue
-83.8% | 6,049.3%
EBITDA
-80.4% | 145.6%
EBIT
-76.3% | 565.9%
Net Income
-60.5% | 144.0%
Free Cash Flow
-156.1%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
-2,471.8% | 14.7%
EBIT
-2,517.0%
Net
-2,128.6% | 12.3%
Free Cash Flow
-2,201.9%
More
EPS
DKK-16.8
FCF per Share
DKK-17.3
Short interest
-
Employees
335
Rev per Employee
DKK190.0k
Show more

Is Zealand Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Zealand Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Zealand Pharma forecast:

16x Buy
80%
4x Hold
20%

Analyst Opinions

20 Analysts have issued a Zealand Pharma forecast:

Buy
80%
Hold
20%

Financial data from Zealand Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
56 56
84% 84%
100%
- Direct Costs 3.68 3.68
85% 85%
7%
52 52
83% 83%
93%
- Selling and Administrative Expenses 431 431
83% 83%
775%
- Research and Development Expense 1,019 1,019
39% 39%
1,830%
-1,377 -1,377
80% 80%
-2,472%
- Depreciation and Amortization 25 25
21% 21%
45%
EBIT (Operating Income) EBIT -1,402 -1,402
76% 76%
-2,517%
Net Profit -1,186 -1,186
60% 60%
-2,129%

In millions DKK.

Don't miss a Thing! We will send you all news about Zealand Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Head office Denmark
CEO Adam Steensberg
Employees 335
Founded 1997
Website www.zealandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today